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Using microarray technology we studied the genome-wide gene expression proﬁles in the frontal cortex
of APPswe/PS1dE9 mice and age and sex-matched littermates at the age of 2, 3, 6, 9, 12, and 15e18
months to investigate transcriptional changes that are associated with beta amyloid protein (Ab) plaque
formation and buildup. We observed the occurrence of an immune response with glial activation, but no
changes in genes involved in synaptic transmission or plasticity. Comparison of the mouse gene
expression data set with a human data set representing the course of Alzheimer’s disease revealed
a strikingly limited overlap between gene expression in the APPswe/PS1dE9 and human Alzheimer’s
disease prefrontal cortex. Only plexin domain containing 2, complement component 4b, and solute
carrier family 14 (urea transporter) member 1 were signiﬁcantly upregulated in the mouse and human
brain which might suggest a function in Ab pathology for these 3 genes. In both data sets we detected
clusters of upregulated genes involved in immune-related processes. We conclude that the APPswe/
PS1dE9 mouse can be a good model to study the immune response associated with cortical Ab plaques.
 2013 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Alzheimer’s disease (AD) is the most common form of dementia
among older people accounting for 60%e70% of all cases (World
Health Organization and Alzheimer’s Disease International, 2012).
The disease is neuropathologically characterized by the presence of
extracellular deposits of beta amyloid protein (Ab) in senile plaques,
intracellular deposits of hyperphosphorylated tau protein in
neuroﬁbrillary tangles, dystrophic neurites, and by neuropil threads
(Braak et al., 1998). Besides the sporadic form of AD, for which aging
is themain risk factor, mutations in amyloid precursor protein (APP),
presenilin 1 (PSEN1), and presenilin 2 (PSEN2) have been found
to cause autosomal dominant early onset familial AD in a small
number of families (Bertram and Tanzi, 2005). The autosomal
dominant form of AD is a very rare disorder with a prevalence less
than 0.1% (Harvey et al., 2003). Most mutations in these 3 genesNeuroscience, Meibergdreef
)20 566 5512; fax: þ31 (0)20
evier OA license.result in alterations in the level of Ab in the brain and in the isoforms
of Ab being produced, leading to Ab species with a higher propensity
to aggregate. Introducing mutated forms of APP and PSEN1 indi-
vidually or in combination into mice has led to the development of
a variety of transgenic mouse lines that model aspects of Ab
pathology (Wisniewski and Sigurdsson, 2010). These mouse models
have contributed signiﬁcantly to our understanding of the molec-
ular processes associated with plaque formation. It is, however,
unclear whether the molecular alterations that cause plaque
formation in models for familial AD also occur in nonfamilial,
sporadic forms of AD. The suitability of current ADmousemodels for
studying sporadic AD therefore warrants further investigation.
We have recently performed a genome-wide gene expression
study in the human prefrontal cortex during the progression of
sporadic AD (Bossers et al., 2010a). One of the most important
ﬁndings was a concerted increase of genes involved in synaptic
transmission and plasticity in nondemented individuals, in the
preclinical stages of AD, just before the onset of plaque pathology in
the prefrontal cortex. In parallel, we observed an increase in
intraneuronal Ab levels. In contrast, after the development of the
ﬁrst plaques and tangles, the expression of these genes, which also
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of Ab, sharply decreased. At the same time patients show memory
impairments. Thus, we hypothesize that the initial increase in
synaptic transmission and plasticity represents a compensatory
reaction to the earliest Ab-related changes in AD.
Our gene expression data in AD provide the unique opportunity
to examine whether similar changes in synaptic activity and plas-
ticity can also be observed in Ab-based AD mouse models. We
therefore have generated genome-wide expression proﬁles from the
frontal cortex of APPswe/PS1dE9 transgenic mice (Jankowsky et al.,
2004) and from their nontransgenic littermates throughout the
entire progression of Ab pathology from 2 to 18 months of age. This
double-transgenic mouse coexpresses APP695 with the Swedish
mutation (K594M/N595L) and the human exon-9-deleted variant of
PSEN1 and develops Ab plaques before 6 months of age (Jankowsky
et al., 2004). These mice also manifest memory deﬁcits as early as
the age of 2 months (Bonardi et al., 2011; Jankowsky et al., 2005;
O’Leary and Brown, 2009; Pillay et al., 2008; Savonenko et al., 2005).
Surprisingly, our gene expression data show that plaque forma-
tion and buildup in the frontal cortex of APPswe/PS1dE9 mice is
solely associated with an increased expression of genes involved in
an immune response and in glial activation, and in this brain region
does not cause any changes in genes associated with memory,
synaptic transmission, and plasticity.
2. Methods
2.1. Animals
In this study we used the double transgenic APPswe/PS1dE9
mouse, line 85 (Jankowsky et al., 2004). For details see The Jackson
Laboratory (strain B6C3-Tg(APPswe,PSEN1dE9)85Dbo/J; stock
number 004462; http://jaxmice.jax.org/). These animals express
chimeric mouse/human APP695 with the Swedish mutation
(K594M/N595L) and the human exon-9-deleted variant of PS1
(PS1dE9) under independent mouse prion protein promoters. AD
mice were maintained as hemizygous and crossed with wild type
(WT) C57BL/6. Genotyping was performed by real-time polymerase
chain reaction (PCR) assays speciﬁc for the 2 transgenes and the
prion promotor. All animals were housed under standard conditions
with access to water and food ad libitum. For microarray and
quantitative PCR (qPCR) experiments, 3 male and 3 female trans-
genic APPswe/PS1dE9 mice were used at each age (2, 3, 6, 9, 12, and
15e18 months) studied. WT littermate mice served as age- and sex-
matched control animals (2 male, 2 female per age group). For
immunoblot analysis, additional APPswe/PS1dE9 mice at the age of
3 (n ¼ 2), 6 (n ¼ 3), 9 (n ¼ 1), and 18 (n ¼ 3) months were used.
Immunohistochemistry was performed on animals also used for
microarray, qPCR, or immunoblot studies. Animal handling and
experimental procedures were reviewed and approved by the
ethical committee for animal care and use of experimental animals
of the Royal Netherlands Academy for Arts and Sciences, acting in
accordance with the European Community Council directive of
November 24,1986 (86/609/EEC). All efforts weremade tominimize
suffering and number of animals used for the study presented here.
2.2. Tissue harvesting
Animals were anesthetized with CO2/O2 and decapitated. The
gray matter of the right frontal cortex was isolated, snap-frozen in
liquid nitrogen, and stored at 80 C for subsequent RNA or protein
isolation. The left hemisphere was immersion ﬁxed in phosphate-
buffered 4% paraformaldehyde (PFA/PBS, pH 7.4) overnight at
4 C. After ﬁxation the tissue was cryoprotected in phosphate
buffered saline (PBS) containing 20% sucrose for a minimum of 5hours at 4 C, embedded in Tissue-Tek (Sakura Finetek Europe,
Alphen aan de Rijn, the Netherlands), frozen on dry ice, and stored
at 80 C to be used for immunohistochemical analysis.
2.3. RNA isolation
RNA was isolated using a combination of TRIzol (Invitrogen
Life Technologies, Carlsbad, CA, USA)-based and RNeasy Mini
Kit (Qiagen, Hilden, Germany) RNA isolation methods. Brieﬂy,
frozen cortex tissue was homogenized in ice-cold 500 mL TRIzol and
centrifuged at 12,000 g for 10 minutes. The supernatant was
transferred to a new tube and vigorously mixed with 100 mL chlo-
roform. Samples were loaded onto a Phase Lock Gel tube (5 Prime,
Hamburg, Germany) and centrifuged at 12,000 g for 15 minutes.
The aqueous phase was collected, mixed with an equal amount of
70% ethanol, applied to an RNeasy spin column and further pro-
cessed according to the manufacturer’s instructions. RNA was
eluted in RNase-free water and stored at 80 C. RNA purity and
yields were determined by a NanoDrop ND-1000 spectrophotom-
eter (NanoDrop Technologies, Wilmington, DE, USA). RNA integrity
was determined by the RNA integrity number, as measured by the
Agilent 2100 bioanalyzer (Agilent Technologies, Palo Alto, CA, USA).
The isolated RNA was of high integrity (average RNA integrity
number 8.7, ranging from 7.3e9.5).
2.4. RNA labeling and microarray hybridization
For microarray analysis, the Whole Mouse Genome Microarray
Kit with 4  44000 probes was used (Agilent Technologies, Part
Number G4122F). RNA labeling and microarray hybridization were
performed according to the manufacturer’s instructions. In short,
for each sample 1 mg total RNA was linearly ampliﬁed and ﬂuo-
rescently labeled with either Cy3- or Cy5-cytosine triphosphate
using the Agilent Low RNA Input Fluorescent Linear Ampliﬁcation
Kit (Agilent Technologies). Before hybridization, equal amounts
(825 ng) of Cy3-labeled and Cy5-labeled complementary RNAwere
mixed and fragmented in 1 fragmentation buffer (Agilent Tech-
nologies) at 60 C for 30minutes. The samplemix was hybridized to
a microarray in 1 Hi-RPM Hybridization Buffer (Agilent Technol-
ogies) at 65 C for 17 hours in a rotating hybridization chamber.
A detailed description of all hybridizations for both the transgenic
and wild type animals can be found in Supplementary Fig. 1.
After hybridization, microarrays were washed in 6 saline
sodium phosphate-EDTA (SSPE)/0.005% N-Lauroylsarcosine for 5
minutes (Sigma-Aldrich, St. Louis, MO, USA), in 0.06x SSPE/ 0.005%
N-Lauroylsarcosine for 1 minute and acetonitrile (Sigma-Aldrich)
for 30 seconds, then dried in a nitrogen ﬂow.
The microarrays were scanned with an Agilent DNA Microarray
scanner at 100% photomultiplier tube setting and 5 mm resolution.
Microarray scans were quantiﬁed using Agilent Feature Extraction
software (version 9.5.3).
2.5. Microarray normalization and single gene analysis
Raw expression data were analyzed in R statistical processing
software (version 2.6.0) using the LIMMA package (Smyth, 2004) in
Bioconductor (http://www.bioconductor.org). All features that were
ﬂagged as saturated or as a nonuniformity outlier by the feature
extraction software on 1 or more arrays were excluded from further
analysis. This was applicable for 2039 features, resulting in 39,136
features which passed these criteria. Data were normalized using
LIMMA by applying a background correction (using the ‘normexp’
algorithm) followed by normalization of intensity distributions
within and between arrays (using the ‘quantile’ algorithm). We have
recently demonstrated that the analysis of the separate intensity
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ducible results than the standard ratio-based approach (the ratio
between the Cy3 and Cy5 channels) for dual-color microarray
datasets (Bossers et al., 2010b), so we also applied this approach for
the present dataset. Thus, the 2log-transformed intensity measure-
ments per samplewere extracted from the normalized ratio data and
used in all following analyses.
To detect genes with a signiﬁcant interaction between age and
genotype, we performed a 2-way analysis of variance (ANOVA) using
age and genotype as grouping factors. The BenjaminieHochberg
method was used to correct for multiple testing. p-values < 0.05
after correction were considered signiﬁcant. A separate analysis for
differences between genotypes in each age group using Student
t tests revealed very similar differentially regulated genes as the
ANOVA and is, therefore, not further considered here.
2.6. Cluster analysis of gene expression proﬁles
To follow the expression of individual transcripts over time we
constructed time proﬁles of each transcript per genotype. Speciﬁ-
cally, for each transcript, mean expression values for each age group
were determined by averaging the individual intensity measure-
ments. Expression values were normalized against the mean
expression of all 2-month-old animals. Cluster analysis was per-
formed to detect groups of transcripts with similar expression
proﬁles (fuzzy clustering with the Mfuzz package, version 2.6.1 in
Bioconductor). The fuzziness parameter M was determined by
optimizing the detection of clusters as described in the Mfuzz
manual, resulting in an M value of 1.3 that was used for further
analysis. The microarray expression dataset was clustered into
8 separate clusters that allowed for the detection of small differ-
ences in expression proﬁles between gene clusters.
2.7. GO analysis of gene clusters
To gain insight into the biological functions that are associated
with the gene clusters, overrepresented Gene Ontology (GO) classes
associated with these clusters were determined with the GoStat
program (http://gostat.wehi.edu.au) (Beißbarth and Speed, 2004),
using all genes on the array as a background dataset. GoStat output
was corrected for multiple testing with the BenjaminieHochberg
method. The ﬁrst 30 GO classes with a p value < 0.001 which
contained more than 5 genes, for which at least 1 gene was rep-
resented in the cluster under investigation, are presented in the
ﬁnal results (Table 2). GoStat does not allow for an evaluation of
whether a signiﬁcant ‘parental branch’ can be solely explained by
its children.
2.8. Ingenuity pathway analysis of regulated genes
We performed a pathway analysis for all genes from cluster 4
and 8 (the clusters that showed a strong expression regulation over
time). Ingenuity Pathway Analysis software (version 7.6; Ingenuity
Systems, Mountain View, CA, USA) was used to identify direct and
indirect physical and/or functional interactions between genes and/
or their protein products. To keep the results relevant for Ab
deposition and AD related processes we included only signiﬁcantly
enriched canonical pathways in the ﬁnal results table which were
not related to a speciﬁc disease and contained at least 3 molecules.
2.9. Real-time qPCR conﬁrmation
All qPCR experiments were performed on the same animals that
were used for the microarray study. The time points 2, 3, 6, 9, 12, and
15e18 months were evaluated. For each sample 1 mg total RNA wasreverse transcribed using the QuantiTect Reverse Transcription Kit
(Qiagen) according to the manufacturer’s protocol. As negative
control, samples of each batch of reverse transcription were pooled
and incubated with primer mix lacking reverse transcriptase.
The obtained cDNA was stored at 20 C until use. Primers were
designed using Primer3 (http://frodo.wi.mit.edu) (Rozen and
Skaletsky, 2000). Primer sequences are listed in Supplementary
Table 1. For each primer pair, dissociation curves were generated to
assess speciﬁcity. Only single products and no primer dimers were
detected. Each qPCR reaction contained 1.5 mL 2 mM primer solution,
5 mL SYBR GreenMaster mix (Applied Biosystems) and 2.86 ng cDNA
in a 10 mL reaction volume. The reaction was run at default settings
(95 C,15 seconds; 60 C, 1 minute; 40 cycles) on the ABI Prism 7300
sequence detection system (Applied Biosystems). Samples were
normalized to the housekeeping genes 28S, Gapdh, and b-actin that
are not regulated between different ages in the mice used. Normal-
ization factors were determined using the GeNorm (Vandesompele
et al., 2002) VBA applet (version 3.5) for Microsoft Excel.
2.10. Immunohistochemistry
Ten-mm cryostat sections were mounted on Superfrost Plus slides
(Thermo Scientiﬁc Menzel, Braunschweig, Germany). Sections were
stored at 80 C or 20 C until use. Cryosections were dried for
15 minutes and ﬁxed in 4% PFA/PBS (pH 7.4) for 3 minutes. Antigen
retrieval was performed in 10 mM sodium citrate (pH 6.0)/0.05%
Tween-20 for 20 minutes at 95 C. For the immunohistochemical
detection of Ab, an additional pretreatment with 70% formic acid for
10minuteswasperformed. Sectionswere thenblockedwith10% fetal
calf serum (FCS) in PBS/0.4% Triton-X 100 for 1 hour at room
temperature. Thereafter, sections were incubated with monoclonal
antibody 4G8 (Signet Laboratories, Dedham, MA, USA; 1:10,000) in
PBS/0.4% Triton-X 100 for 1 hour at room temperature. Next, sections
were incubatedwith biotinylated horse anti-mouse antibody (Vector
Laboratories, Burlingame, CA, USA; 1:400) in PBS/1% FCS for 1 hour
at room temperature. Sections were incubated in ABC solution
(Vector Laboratories) for 1 hour at room temperature, followed by
a 5-minute incubation with 3,3’-diaminobenzidine as chromogen.
Sections were dehydrated in a graded ethanol series followed by
xylene and embedded with entellan glue. For quantiﬁcation of Ab
load, tiled photographs of the whole section were taken with
a XC-77CE CCD monochrome camera (Sony, Badhoevedorp, The
Netherlands) through a 10 objective connected to an Axioskop
microscope (Zeiss, Jena, Germany). Analysis of the cortex area
covered with Ab plaques was done using the Image-Pro Plus soft-
ware (version 6.0, Media Cybernetics, Bethesda, MD, USA) with
a computer-generated mask manually overlaid on the cortex, which
recognized 3,3’-diaminobenzidine staining. Plaque load was evalu-
ated in all animals used for the microarray and qPCR studies.
For immunoﬂuorescent stainings of glial-ﬁbrillary acidic protein
(GFAP), allograft inﬂammatory factor 1 (IBA1), and complement
component 4b (C4B), cryostat sections of 3- and 15e18-month-old
animals were used (4 transgenic animals per age group: 4 males at
3 months, 2 males and 2 females at 15e18 months; 2 WT male
animals per age group). Tissue from 6 transgenic animals and the
WT animals were also used in the microarray study; tissue from
2 transgenic animals was used in the immunoblot experiments.
Fixation and retrieval were performed as described above. Primary
antibodies were rabbit anti-C4B (Abcam, Cambridge, UK; 1:300),
rabbit anti-IBA1 (Wako Chemicals, Neuss, Germany; 1:600) and
rabbit anti-GFAP (Dako, Glostrup, Denmark; 1:2000) in PBS/0.4%
Triton-X 100/3% FCS overnight at 4 C. Cy3-conjugated donkey anti
rabbit IgG (Jackson Immuno Research, Newmarket, Suffolk, UK;
1:1000) in PBS/0.4% Triton-X 100/1% FCS was used as secondary
antibody for 2 hours at room temperature. Ab plaques were
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minutes. Sections were then treated with Hoechst (Invitrogen;
1:20,000) in PBS for 10 minutes to visualize cell nuclei and
mounted with Mowiol embedding medium. Photographs were
taken using an Axioplan 2 ﬂuorescent microscope (Zeiss) con-
nected to an MP digital camera (MediaCybernetics) with a 20
objective.
2.11. Western blot analysis
The frozen right hemisphere cortex samples were homoge-
nized in suspension buffer (0.1 M NaCl, 0.01 M Tris-HCl, 0.001 M
ethylenediaminetetraacetic acid) containing protease inhibitors
(20 mM antipain, 1 mM pepstatin, 20 mM chymostatin, 10 mg/mL
leupeptin, and 100 mg/mL phenylmethanesulphonylﬂuoride)
using an ultra turrax tissue homogenizer. Homogenates were
centrifuged at 14,000 rpm for 5 minutes at 4 C, the supernatant
was collected and protein concentrations were measured using
a bicinchoninic acid protein assay kit (Pierce, Thermo Scientiﬁc,
Rockford, IL, USA). Immunoblotting experiments were performed
for GFAP, C4B, and IBA1 using the same antibodies as for the
immunostainings. For each sample, 26.8 mg protein was heated in
5 loading buffer containing 10% sodium dodecyl sulphate and
10% b-mercaptoethanol at 95 C for 10 minutes. Tris-glycine
sodium dodecyl sulphate polyacrylamide gel electrophoresis was
performed using the BioRad Mini-PROTEAN 3 gel electrophoresis
system (Bio-Rad Laboratories, Hercules, CA, USA). Gels contained
8% (C4B), 12% (GFAP), and 15% (IBA1) acrylamide/bisacrylamide.
Proteins were transferred to nitrocellulose membranes using
a semidry (GFAP and IBA1) or wet (C4B) blotting procedure and
blocked with 5% fat-free milk powder in PBS/0.05% Tween-20 for 1Fig. 1. Beta amyloid protein (Ab) plaque pathology increased with age in APPswe/PS1dE9 mi
left hemisphere of the frontal cortex. First plaques were detected at 6 months of age and plaq
type mouse cortex (upper left), is shown together with representative examples from APPsw
mm. (B) Quantiﬁcation of plaque load in the frontal cortex of APPswe/PS1dE9 and wild type m
frontal cortex area that is covered with plaques. The increase of plaque load over time is signi
load with age and are pooled for the quantiﬁcation. Abbreviations: TG, transgenic; WT, wilhour at room temperature. Blots were incubated with antibodies
against GFAP, C4B (diluted in PBS/0.05% Tween-20/5% milk) or
IBA1 (diluted in supermix: 0.25% gelatin, 0.5% Triton-X 100 in PBS,
pH 7.4) for 2 hours at room temperature or 4 C overnight. b-actin
(Sigma-Aldrich; 1:2000) was used as a loading control. Primary
antibodies were detected with an IR800 antibody (Rockland
Immunohistochemicals, Gilbertsville, PA, USA; 1:5000) and
b-actin was detected with a Cy5-conjugated antibody (Jackson
Immuno Research; 1:2000) for 2 hours at room temperature. Blots
were scanned and analyzed using the Odyssey Infrared Imager and
Odyssey 2.1 scanning software (LI-COR Biosciences, Lincoln, NE,
USA). The b-actin signal was used to normalize the ﬁnal protein
quantiﬁcations.3. Results
3.1. Ab plaque pathology in APPswe/PS1dE9 mice increases with age
We ﬁrst conﬁrmed the previously documented plaque
pathology in our mouse colony. Immunohistochemical detection of
Ab, using the 4G8 antibody, in brain sections of the APPswe/PS1dE9
transgenic mice showed that Ab plaque load in the frontal cortex
increased with age (Fig. 1). The ﬁrst plaques were detected at the
age of 6 months. This is in good agreement with earlier reports
showing that these mice show plaques from very early in age
(Garcia-Alloza et al., 2006; Jankowsky et al., 2004; Kamphuis et al.,
2012; Ruan et al., 2009). As the plaque load in the frontal cortex of
APPswe/PS1dE9 mice did not change between 15 and 18 months of
age (3.610.5% vs. 3.651.2%; p> 0.05), we combined these 2 age
groups for the gene expression analysis.ce. (A) Ab plaques were stained with the monoclonal anti-amyloid 4G8 antibody on the
ue burden increased with age. A representative example picture of a 2-month-old wild
e/PS1dE9 transgenic mice at the age of 2, 3, 6, 9, 12, 15, and 18 months. Scale bar: 0.2
ice for all age groups (n ¼ 6 per group). Plaque load is represented in percentage of the
ﬁcant (analysis of variance; p < 0.001). Wild type animals do not show increased plaque
d type.
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coincides with plaque development
To determine the gene expression changes that are speciﬁcally
associated with Ab pathology, microarrays were used to assess the
transcriptional alterations that occur during the development of
plaque pathology in the frontal cortex of APPswe/PS1dE9 mice, and
we compared thesewith age-related gene expression changes in age-
matched wild type littermates. A total of 87 transcripts showed
a signiﬁcant interaction between age and genotype (ANOVA-based
p value < 0.05, Table 1). All signiﬁcantly regulated transcripts were
upregulated over time. No genes were detected that showed a tran-
scriptional downregulation with age and plaque development.
Among the signiﬁcantly upregulated genes were many genes
involved in the regulation of immune function such as a large group
of Cluster of differentiation (Cd) antigens (Cd9, Cd14, Cd48, Cd52,
Cd68, Cd84, Cd86, Cd180, Cd300d, Cd300lf, Fcgr2b, Fcgr3, Itgax,
Lair1, Lilrb4, Pdcd1, Siglecf, Tlr2, Tnfsf13b), chemokine ligands (Ccl3,
Ccl4, Ccl6, Cxcl5), and members of the complement system (C1qc,
C4b). The microglia marker allograft inﬂammatory factor 1 (Aif1/
Iba1) and the astrocyte marker glial ﬁbrillary acidic protein (Gfap)
were 2.2- and 7.9-fold upregulated, respectively. Furthermore, we
found genes involved in lipid metabolism (Apobec1, Apoc4, Ch25h,
Lpl) and cathepsins (Ctsc, Ctsh, Ctsz) to be upregulated.
Next, we performed a cluster analysis on the expression proﬁles
of all genes over time in both the APPswe/PS1dE9 transgenic
animals and in wild type controls to detect groups of genes with
concerted patterns of expression. In theAPPswe/PS1dE9mouse, this
cluster analysis revealed 2 clusters (4 and 8) in which transcripts
showed an upregulation starting between 3 and 6 months of age;
coinciding with the development of Ab plaque pathology (Fig. 2A).
Cluster 8 contained the transcripts with the highest fold changes.
Transcripts in cluster 4 also showed a continuous upregulation over
time but with lower fold changes. Before the onset of plaque
pathology, at the 2- and 3-month time points, no gene regulation
was detected. Clusters of transcripts of wild type animals did not
show any signiﬁcant changes in their time proﬁle (data not shown).
We selected a set of 17 regulated genes (Bcl3, synaptogyrin 1
[Syngr1], Baiap2l2, Birc1b, activating transcription factor 3 [Atf3],
Itgax, Pdcd1, Ccl6, Gpr109a, Tlr2, Trem2, Iba1, Tyropb, Cd9, Bcl2a1b,
Igf1, Gfap) to validate the microarray data using qPCR. For all
selected genes the patterns of gene expression over time were
highly correlated between the microarray and qPCR measurements
(R2  0.96; p < 0.001; example plots see Fig. 2B) for the APPswe/
PS1dE9 mice. Furthermore, fold change between APPswe/PS1dE9
and wild type at 15e18 months as measured by qPCR showed
a strong linear correlation with the microarray-derived fold change
at that same time point (R2 ¼ 0.85; p < 0.001; Fig. 2C).3.3. Functional annotation and pathway analysis: immune
response is induced after plaque formation
To investigate which biological processes were associated with
the upregulated genes in APPswe/PS1dE9 mice, we performed a GO
overrepresentation analysis on the upregulated clusters 4 and 8.
This analysis revealed that these clusters were highly enriched for
transcripts involved in immune response-associated processes,
such as the biological process GO classes ‘immune system process,’
‘defense response,’ ‘response to external stimulus,’ and ‘response to
wounding and inﬂammatory response’ (see Table 2 for the 30 most
signiﬁcant GO identiﬁers and Supplementary Table 2 for the
complete list [p < 0.01]). Overrepresented cellular component GO
classes were among others ‘cell surface,’ ‘MHC I and II protein
complex,’ and ‘lysosome’. Prominent overrepresented GO classes ofmolecular function were ‘immunoglobulin binding,’ and ‘chemo-
kine and cytokine activity.’
In addition to the GO overrepresentation analysis we performed
an Ingenuity Pathway analysis on the upregulated clusters 4 and 8.
The canonical pathways that were signiﬁcantly enriched included
Dendritic Cell Maturation, Role of Pattern Recognition Receptors in
Recognition of Bacteria and Viruses, T Helper Cell Differentiation,
Antigen Presentation Pathway and Communication between Innate
and Adaptive Immune Cells (see Supplementary Table 3 for the full
list of overrepresented pathways). The results of the Ingenuity
Pathway analysis and GO analysis were thus in general agreement
with each other.
3.4. IBA1, GFAP, and C4B protein levels corroborate the gene
expression data
Gene expression data indicated an immune and glial response in
APPswe/PS1dE9 mice including the upregulation of Iba1, Gfap, and
complement component 4b (C4b). We therefore studied whether
microgliosis, astrogliosis, and inﬂammationwere also present on the
protein level using antibodies against IBA1, GFAP, and C4B, respec-
tively. Analysis of the immunoreactivity levels revealed that IBA1,
GFAP, andC4Bproteinwerehighly upregulated in the frontal cortexof
APPswe/PS1dE9 mice at 15 months of age (when plaques were
abundantly present) compared with age-matched wild type animals
without plaque pathology (Fig. 3A). GFAP staining was observed in
activated astroglia distributed uniformly over the frontal cortexwhile
and IBA1 immunoreactivity was clearly detectable in activated
microglia around plaques. C4B staining was strongly visible in
microglia forming an outer rim around the plaques. To quantify
protein expression levels, we performed Western blot analysis of
IBA1, GFAP, and C4B in the frontal cortex of APPswe/PS1dE9 mice
(Fig. 3B). Quantiﬁcation of the immunoblots revealed that GFAP and
IBA1 protein expression signiﬁcantly increased over time (ANOVA,
p < 0.05). We observed a mild, but nonsigniﬁcant, increase of C4B
protein expression (ANOVA, p ¼ 0.5; p ¼ 0.28 when an outlier was
removed). Wild type animals did not show signiﬁcant changes in
protein expression ofGFAP, IBA1, andC4B over time (data not shown).
3.5. Plaque formation is not associated with transcriptional
alterations of genes involved in synaptic activity or plasticity
Changes in synaptic transmission and plasticity related genes
occur early in AD patients in Braak stages 2 and 3 (Bossers et al.,
2010a). However, in APPswe/PS1dE9 mice the analysis of differen-
tial gene expression and the GO analysis did not reveal transcrip-
tional alterations in genes that have a function in synaptic activity
or plasticity during Ab plaque formation. To conﬁrm that key
synaptic genes were indeed not regulated in APPswe/PS1dE9 mice
we performed an extensive qPCR analysis for the time points 2, 3, 6,
9, 12, and 15e18 months. The selection of synaptic genes was based
on 2 criteria. First, 14 genes were selected that have been investi-
gated in another very similar APPþPS1mousemodel for AD (Dickey
et al., 2003; see Fig. 4 and Supplementary Table 1 for a speciﬁcation
of the studied genes and primer sequences). Seven of those genes
were reported to be downregulated. Like the APPswe/PS1dE9
mouse, the APPþPS1 mouse carries the Swedish mutation of APP
(K670N, M671L), but a different PS1 mutation (M146L) (Holcomb
et al., 1998). Second, 9 genes were selected because these have
been shown to be regulated in a recent microarray study in human
postmortem prefrontal cortex tissue of AD patients (Bossers et al.,
2010a). The qPCR analysis showed that only 3 well-
studied synaptic genesdearly growth response 1 (Egr1), activity
regulated cytoskeletal-associated protein (Arc), and nuclear
receptor subfamily 4, group A, member 1 (Nr4a1)dshowed a trend
Table 1
List of signiﬁcantly altered transcripts in APPswe/PS1dE9 transgenic mice during the development of beta amyloid protein (Ab) pathology





Cst7 Mus musculus cystatin F (leukocystatin) (Cst7),
mRNA [NM_009977]
0.4 0.44 3.78 5.58 6.93 7.17 2.29Ee11 109.14 8
Itgax Mus musculus integrin alpha X (Itgax), mRNA [NM_021334] 0.58 0.12 1.56 3.29 4.66 5.26 3.04Ee06 35.26 8
Clec7a Mus musculus C-type lectin domain family 7, member a
(Clec7a), mRNA [NM_020008]
0.13 0.11 1.7 3.42 4.19 4.72 2.45Ee06 28.84 8
Ccl3 Mus musculus chemokine (C-C motif) ligand 3 (Ccl3),
mRNA [NM_011337]
0.17 0 2.14 3.65 4.38 4.59 2.47Ee07 24.08 8
C4b Mus musculus complement component 4B
(Childo blood group) (C4b), mRNA [NM_009780]
0.36 0.27 1.8 2.79 3.9 4.54 3.74Ee04 19.29 8
Ccl4 Mus musculus chemokine (C-C motif) ligand 4 (Ccl4),
mRNA [NM_013652]
0.04 0.05 1.5 2.85 3.78 3.98 3.98Ee09 16.34 8
Gpnmb Mus musculus glycoprotein (transmembrane) nmb (Gpnmb),
mRNA [NM_053110]
0.15 0.12 0.73 1.63 3 4.06 1.32Ee05 15.35 8
Gpr109 Mus musculus G protein-coupled receptor 109A (Gpr109a),
mRNA [NM_030701]
0.13 0.02 1.1 2.53 3.46 3.84 4.56Ee08 14.52 8
Ccl6 Mus musculus chemokine (C-C motif) ligand 6 (Ccl6),
mRNA [NM_009139]
0.09 0.25 1.71 3.04 3.84 3.83 2.77Ee09 13.45 8
Pdcd1 Mus musculus programmed cell death 1 (Pdcd1),
mRNA [NM_008798]
0.09 0.14 1.28 2.43 3.18 3.62 2.77Ee06 11.55 8
Igf1 Mus musculus insulin-like growth factor 1 (Igf1),
mRNA [NM_010512]
0.01 0.3 0.24 1.27 2.43 2.85 1.92Ee11 8.88 8
Gfap Mus musculus glial ﬁbrillary acidic protein (Gfap),
mRNA [NM_010277]
0.03 0 1.12 1.8 2.41 2.99 0.014 7.94 8
Trem2 Mus musculus triggering receptor expressed on myeloid
cells 2 (Trem2), mRNA [NM_031254]
0.01 0.21 0.84 1.84 2.62 2.95 2.38Ee06 7.67 8
Spp1 Mus musculus secreted phosphoprotein 1 (Spp1),
mRNA [NM_009263]
0.09 0.17 0.13 0.71 1.68 2.74 3.16Ee04 7.52 8
Bcl3 Mus musculus B-cell leukemia/lymphoma 3 (Bcl3),
mRNA [NM_033601]
0.08 0.28 0.17 1.03 1.79 2.49 0.033 6.82 8
Bcl2a1b Mus musculus B-cell leukemia/lymphoma 2 related
protein A1b (Bcl2a1b), mRNA [NM_007534]
0.02 0.25 0.24 1.69 2.3 2.51 4.04Ee04 6.77 8
Cd300lf Mus musculus CD300 antigen like family member F (Cd300lf),
mRNA [NM_145634]
0.03 0.15 0.82 2.1 2.4 2.45 1.22Ee06 6.06 8
Tlr2 Mus musculus toll-like receptor 2 (Tlr2), mRNA [NM_011905] 0 0.1 0.74 1.71 2.34 2.49 0.001 6.02 8
Ch25h Mus musculus cholesterol 25-hydroxylase (Ch25h),
mRNA [NM_009890]
0.05 0.14 0.38 1.56 2.19 2.43 6.49Ee05 5.94 8
Cd68 Mus musculus CD68 antigen (Cd68), mRNA [NM_009853] 0.23 0.14 0.81 1.57 2.42 2.63 0.022 5.62 8
Tyrobp Mus musculus TYRO protein tyrosine kinase
binding protein (Tyrobp),
mRNA [NM_011662]
0.02 0.03 0.59 1.67 2.3 2.44 4.02Ee06 5.50 8
Fcgr2b Mus musculus Fc receptor, IgG, low afﬁnity IIb (Fcgr2b),
mRNA [NM_001077189]
0 0.23 0.29 1.26 2.06 2.22 6.13Ee06 5.46 8
Lzp-s Mus musculus P lysozyme structural (Lzp-s),
mRNA [NM_013590]
0.22 0.25 0.53 2 2.49 2.66 0.005 5.43 8
St14 Mus musculus suppression of tumorigenicity 14
(colon carcinoma) (St14), mRNA [NM_011176]
0.15 0.15 0.82 1.56 2.33 2.58 0.008 5.39 8
Cd52 Mus musculus CD52 antigen (Cd52), mRNA [NM_013706] 0.23 0.2 1.06 2 2.6 2.62 9.33Ee04 5.35 8
Cxcl5 Mus musculus chemokine (C-X-C motif) ligand 5 (Cxcl5),
mRNA [NM_009141]
0.18 0.05 0.63 1.41 2.15 2.23 0.001 5.31 8
Gpr65 Mus musculus G-protein coupled receptor 65 (Gpr65),
mRNA [NM_008152]
0.07 0.09 0.64 1.64 2.04 2.32 2.42Ee09 5.31 8
Cd14 Mus musculus CD14 antigen (Cd14), mRNA [NM_009841]
A430060F13Rik Mus musculus 2 cells egg cDNA, RIKEN full-length
enriched library, clone:B020003F03 product:hypothetical protein,
full insert sequence. [AK139527]
0.11 0.05 0.62 1.37 2.11 2.42 4.00Ee03 5.17 8
Mamdc2 Mus musculus MAM domain containing 2 (Mamdc2),
mRNA [NM_174857]
0.04 0.05 0.09 0.49 1.62 2.28 6.93Ee09 5.17 8
4930431B09Rik Mus musculus cDNA clone IMAGE:6306854,
partial cds. [BC046309]
0.05 0.17 0.84 1.62 2.4 2.39 6.13Ee06 5.10 8
Asb10 Mus musculus ankyrin repeat and SOCS box-containing
protein 10 (Asb10), Mrna [NM_080444]
0 0.18 0.46 1.38 2 2.15 0.03 5.03 8
AU020206 Mus musculus 7 days embryo whole body cDNA, RIKEN
full-length enriched library, clone:C430005K08
product:unclassiﬁable, full insert sequence [AK049415]
0 0.12 0.85 1.92 2.28 2.32 2.73Ee07 4.99 8
Osmr Mus musculus oncostatin M receptor (Osmr),
mRNA [NM_011019]
0.01 0.15 0.18 0.96 1.41 2.14 1.39Ee08 4.89 8
Ly86 Mus musculus lymphocyte antigen 86 (Ly86),
mRNA [NM_010745]
0.08 0.03 0.6 1.55 2.08 2.2 4.70Ee10 4.86 8
Cd84 Mus musculus CD84 antigen (Cd84), mRNA [NM_013489] 0.06 0.15 0.51 1.41 1.85 2.08 1.54Ee06 4.69 8
Slc15a3 Mus musculus solute carrier family 15, member 3 (Slc15a3),
mRNA [NM_023044]
0.07 0.21 0.5 1.21 1.95 2.01 0.026 4.66 8
Syngr1 Mus musculus synaptogyrin 1 (Syngr1), transcript variant
1b, mRNA [NM_009303]
0.08 0.1 0.53 1.34 2.11 2.3 0.003 4.66 8
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Slc11a1 Mus musculus solute carrier family 11 (proton-coupled divalent
metal ion transporters), member 1 (Slc11a1),
mRNA [NM_013612]
0.17 0.01 0.63 1.41 2.05 2.21 0.029 4.59 8
Siglecf Mus musculus sialic acid binding Ig-like lectin F (Siglecf),
mRNA [NM_145581]
0.03 0.18 0.52 1.54 1.9 1.94 6.49Ee05 4.35 8
5430435G22Rik Mus musculus RIKEN cDNA 5430435G22 gene (5430435G22Rik),
mRNA [NM_145509]
0.05 0.48 0.03 0.6 1.34 1.56 9.60Ee09 4.11 8
Irf8 Mus musculus interferon regulatory factor 8 (Irf8),
mRNA [NM_008320]
0.15 0.08 0.64 1.34 1.93 2.08 0.011 4.00 8
Ctsz Mus musculus cathepsin Z (Ctsz), mRNA [NM_022325] 0.13 0.21 0.83 1.44 1.94 2.04 0.009 3.76 8
Lrmp Mus musculus lymphoid-restricted membrane protein (Lrmp),
mRNA [NM_008511]
0.09 0.19 0.95 1.35 1.67 1.94 5.54Ee05 3.61 8
Pon3 Mus musculus paraoxonase 3 (Pon3), mRNA [NM_173006] 0.02 0.14 0.32 0.98 1.54 1.7 0.004 3.58 8
Samsn1 Mus musculus SAM domain, SH3 domain and nuclear localization
signals, 1 (Samsn1), mRNA [NM_023380]
0.05 0.21 0.21 0.9 1.29 1.61 0.002 3.53 8
Cd9 Mus musculus CD9 antigen (Cd9), mRNA [NM_007657] 0.13 0 0.57 1.12 1.61 1.78 1.13Ee06 3.43 4
Ebi2 Mus musculus Epstein-Barr virus induced gene 2 (Ebi2),
mRNA [NM_183031]
0.02 0.26 0.05 0.73 1.28 1.5 7.31Ee04 3.39 8
Mpeg1 PREDICTED: Mus musculus macrophage expressed gene 1,
transcript variant 1 (Mpeg1), mRNA [XM_129176]
0.09 0.25 0.24 1.06 1.49 1.5 6.02Ee04 3.36 8
Atf3 Mus musculus activating transcription factor 3 (Atf3),
mRNA [NM_007498]
0.1 0.13 0.64 1.21 1.75 1.84 0.036 3.34 8
Gusb Mus musculus glucuronidase, beta (Gusb), mRNA [NM_010368] 0.08 0.17 0.59 1.27 1.79 1.71 2.59Ee04 3.27 8
Cd300d Mus musculus Cd300D antigen (Cd300d), mRNA [NM_134158] 0.04 0.01 0.29 1 1.52 1.71 7.00Ee04 3.25 8
Birc1b Mus musculus baculoviral IAP repeat-containing 1b (Birc1b),
mRNA [NM_010872]
0.1 0.14 0.5 1.36 1.54 1.51 0.01 3.20 8
C1qc Mus musculus complement component 1, q subcomponent,
C chain (C1qc), mRNA [NM_007574]
0.11 0.06 0.48 0.99 1.52 1.72 0.032 3.16 4
Fcgr3 Mus musculus Fc receptor, IgG, low afﬁnity III (Fcgr3),
mRNA [NM_010188]
0.09 0.04 0.42 1.1 1.61 1.55 0.01 3.14 8
Lair1 Mus musculus leukocyte-associated Ig-like receptor 1 (Lair1),
mRNA [NM_178611]
0.06 0.04 0.52 1.05 1.39 1.57 1.17Ee04 3.10 4
Cybrd1 Mus musculus adult male urinary bladder cDNA, RIKEN
full-length enriched library, clone: 9530059N16
product:cytochrome b reductase 1,
full insert sequence [AK162525]
0.05 0.44 0.21 0.33 0.95 1.19 0.004 3.10 4
Lilrb4 Mus musculus leukocyte immunoglobulin-like receptor,
subfamily B, member 4 (Lilrb4), RNA [NM_013532]
0.17 0.1 0.28 0.84 1.28 1.71 7.03Ee05 3.05 4
Baiap2l2 Mus musculus BAI1-associated protein 2-like 2 (Baiap2l2),
mRNA [NM_177580]
0.19 0.18 0.55 0.89 1.41 1.66 0.017 2.79 4
Slc14a1 Mus musculus solute carrier family 14 (urea transporter),
member 1 (Slc14a1), mRNA [NM_028122]
0.14 0.01 0.29 0.76 1.26 1.46 2.62Ee05 2.77 4
Fyb Mus musculus FYN binding protein (Fyb),
mRNA [NM_011815]
0.12 0.01 0.34 0.94 1.14 1.34 0.031 2.75 4
Msr2 Mus musculus macrophage scavenger receptor 2 (Msr2),
mRNA [NM_030707]
0.01 0.08 0.39 0.87 1.36 1.37 0.017 2.73 4
Apoc4 Mus musculus apolipoprotein C-IV (Apoc4),
mRNA [NM_007385]
0.01 0.15 0.13 0.35 0.82 1.3 6.28Ee04 2.73 4
Hexb Mus musculus hexosaminidase B (Hexb),
mRNA [NM_010422]
0.03 0.05 0.36 0.96 1.25 1.4 7.73Ee05 2.73 4
Tnfsf13b Mus musculus tumor necrosis factor (ligand) superfamily,
member 13b (Tnfsf13b), mRNA [NM_033622]
0.06 0.03 0.28 1.16 1.47 1.47 0.022 2.71 4
Apbb1ip Mus musculus amyloid beta (A4) precursor protein-binding,
family B, member 1 interacting protein (Apbb1ip),
mRNA [NM_019456]
0.16 0 0.2 0.62 0.96 1.21 2.00Ee02 2.58 4
Ctsh Mus musculus cathepsin H (Ctsh), mRNA [NM_007801] 0.01 0.19 0.11 0.7 1.05 1.18 6.45Ee04 2.58 4
Ctsc Mus musculus cathepsin C (Ctsc), mRNA [NM_009982] 0.01 0.23 0.04 0.76 1.03 1.12 0.01 2.55 4
Afp Mus musculus alpha fetoprotein (Afp), mRNA [NM_007423] -0.04 0.13 0.13 0.62 0.84 1.2 0.011 2.51 4
Cd48 Mus musculus CD48 antigen (Cd48), mRNA [NM_007649] 0.06 0.04 0.23 0.91 1.14 1.36 0.043 2.50 4
Klhl6 Mus musculus kelch-like 6 (Drosophila) (Klhl6),
mRNA [NM_183390]
0.04 0.24 0.45 0.85 1.27 1.26 0.002 2.48 4
Cd86 Mus musculus CD86 antigen (Cd86), mRNA [NM_019388] 0.05 0.16 0.09 0.64 0.88 1.12 1.05Ee04 2.43 4
Plxdc2 Mus musculus plexin domain containing 2 (Plxdc2),
mRNA [NM_026162]
0.16 0.1 0.24 0.77 1.05 1.11 2.23Ee05 2.41 4
Lpl Mus musculus lipoprotein lipase (Lpl), mRNA [NM_008509] 0.06 0.15 0.17 0.64 0.99 1.08 0.004 2.35 4
Ptx3 Mus musculus pentraxin related gene (Ptx3),
mRNA [NM_008987]
0.02 0.1 0.11 0.39 0.6 1.05 0.006 2.23 4
B2m Mus musculus beta-2 microglobulin (B2m),
mRNA [NM_009735]
0.08 0.04 0.22 0.79 1.04 1.07 0.008 2.22 4
Aif1 Mus musculus allograft inﬂammatory factor 1 (Aif1, Iba1),
mRNA [NM_019467]
0.08 0.01 0.36 0.79 1.14 1.07 0.005 2.22 4
D14Ertd668e Mus musculus DNA segment, Chr 14, ERATO Doi 668,
expressed (D14Ertd668e), mRNA [NM_199015]
0.07 0.13 0.16 0.7 0.9 1.01 0.027 2.20 4
Hpse Mus musculus heparanase (Hpse), mRNA [NM_152803] 0.09 0.19 0.13 0.31 0.61 0.95 0.018 2.20 4
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Frrs1 Mus musculus ferric-chelate reductase 1 (Frrs1),
mRNA [NM_009146]
0.04 0.12 0.06 0.58 1 0.79 0.004 2.17 4
Rnase4 Mus musculus ribonuclease, RNase A family 4 (Rnase4),
transcript variant 1, mRNA [NM_021472]
0.02 0.1 0.15 0.53 0.83 1.01 0.019 2.16 4
EG328314 Mus musculus adult male corpora quadrigemina
cDNA, RIKEN full-length enriched library,
clone:B230311A21 product: unclassiﬁable,
full insert sequence [AK045784]
0.01 0.04 0.28 0.87 0.99 1.02 0.031 2.08 4
Cd180 Mus musculus CD180 antigen (Cd180), mRNA [NM_008533] 0.04 0.09 0.32 0.86 0.95 0.85 0.047 2.06 4
Btk Mus musculus Bruton agammaglobulinemia tyrosine
kinase (Btk), mRNA [NM_013482]
0.04 0.03 0.21 0.63 0.97 0.9 0.039 2.00 4
Arpc1b Mus musculus actin related protein 2/3 complex, subunit 1B
(Arpc1b), mRNA [NM_023142]
0.02 0.01 0.08 0.56 0.93 0.89 3.68Ee05 1.92 4
Apobec1 Mus musculus apolipoprotein B editing complex 1 (Apobec1),
mRNA [NM_031159]
0.01 0.01 0.02 0.56 0.79 0.94 0.049 1.91 4
Rnaset2 Mus musculus ribonuclease T2 (Rnaset2), transcript variant 1,
mRNA [NM_026611]
0.09 0.02 0.31 0.52 0.81 0.91 2.64Ee04 1.85 4
Cnn3 Mus musculus calponin 3, acidic (Cnn3), mRNA [NM_028044] 0.04 0.06 0.33 0.49 0.69 0.73 0.012 1.61 4
Age data are presented as 2log-transformed fold change against average of all 2-month-old animals (wild type and transgenic). p values are BenjaminieHochberg corrected
ANOVA values. Fold change¼maximum fold change between age groups. Cluster ¼ cluster assignment (see Figure 2). All genes with p< 0.05 are listed. Abbreviations: mRNA,
messenger RNA; Mo, months.
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aged transgenic APPswe/PS1dE9 mice (15e18 months) compared
with age-matched wild type animals. These 3 genes were also re-
ported to be downregulated in the study by Dickey and colleagues
(2003). None of the other synaptic genes, including those that were
found to be changed in the human data set, showed alterations in
mRNA expression. Importantly, for all of the genes, the qPCR data
corroborated the APPswe/PS1dE9 microarray results.
3.6. APPswe/PS1dE9 and human AD data show very limited overlap
To further investigate the similarities and differences between
gene expression changes in the APPswe/PS1dE9 mouse and the
human AD brain, we performed a qPCR study on 8 genes (Bcl2, Btg1,
Cd59, Gtf2i, Mxi1, Slc6a12, Cycs, Chchd2) that we have found to be
consistently regulated in at least 3 out of 5 published human AD
microarray data sets (Blalock et al., 2004; Bossers et al., 2010a;
Emilsson et al., 2006; Parachikova et al., 2007; Xu et al., 2006). None
of these genes showed a signiﬁcant regulation of expression in the
APPswe/PS1dE9 mouse model at 2, 3, 6, 9, 12, and 15e18 months of
age. However, the Bcl-2 like gene Bcl2a1b was signiﬁcantly upre-
gulated on the mouse microarray.
We also investigated whether transcriptional changes that
occurred in APPswe/PS1dE9 mice with developing plaque pathology
were comparable with gene expression changes in the human brain
during the progression of sporadic AD (Bossers et al., 2010a). This data
set contains gene expression data of the gray matter of the prefrontal
cortex before and after plaque development and a comparison with
the APPswe/PS1dE9 data set might thus elucidate whether tran-
scriptional changes associated with Ab plaque development in the
mouse are similar to the human situation. The analysis of the overlap
between the lists of signiﬁcantly regulated genes in the APPswe/
PS1dE9data set (n¼87genes)and thehumandataset (n¼922genes)
revealed that only 3 genes (solute carrier family 14 [urea transporter]
member 1 [Slc14a1], C4b, plexin domain containing 2 [Plxdc2]) were
signiﬁcantly upregulated in both themouse andhumandata setswith
increasing plaque load or Braak stages, respectively.
A comparison of the overrepresented biological process GO
classes in the 2 data sets also revealed a minimal overlap between
mouse and human data. The mouse clusters were associated with
immune response. In the human AD brain, however, the clusters of
downregulated genes are associated with synaptic activity and
plasticity and the clusters with upregulated genes are associatedwith transcription, metal ion binding, differentiation/proliferation
and, as small overlap with the mouse data, antigen processing
(Bossers et al., 2010a). Comparing only the immune response-
related clusters in the APPswe/PS1dE9 mouse and sporadic AD
data, we found that C3, C4B, CXCL10, CXCR4, histocompatibility
complex, class II, DR b 1 (HLA-DRB1), ICOSLG, IRAK3, KLHL6, RGS1,
Serpin peptidase inhibitor, clade A [alpha-1 antiproteinase, anti-
trypsin], member 3 [SERPINA3], TGFB1 and TREM2 were upregu-
lated in both data sets.
4. Discussion
In the present study we used microarray technology to examine
which transcriptional changes occur in the frontal cortex of the
double-transgenic mouse line APPswe/PS1dE9 before, during, and
after the development of dense-core Ab plaques and to compare
these transcriptional alterations to transcriptional changes in the
human AD brain. Only a limited number of studies have explored
genome-wide transcriptional changes at 2 or 3 time points during
the development of Ab plaques in ADmousemodels: in the cerebral
cortex (Reddy et al., 2004) of the Tg2576 (APP695KM670/671NL),
the APPNLh/NLh/PS-1P264L/P264L, the Tg2576/PSP264L/P264L, and the
Tg2576/PSP264L/þ mouse (Wu et al., 2006), and the hippocampus
and cortex of the PDAPP (APPV717) mouse (Selwood et al., 2009). The
results from these experiments were remarkably diverse and
included the upregulation of apoptotic genes (Reddy et al., 2004),
the upregulation of genes involved in mitochondrial energy
metabolism (Reddy et al., 2004), the upregulation of carbohydrate
metabolism and proteolysis (Wu et al., 2006), the downregulation
of transcription and translation (Selwood et al., 2009), the upre-
gulation of immune response related genes (Wu et al., 2006) and
the downregulation of genes involved in neuronal survival
(Selwood et al., 2009; Wu et al., 2006). These studies investigated
genome-wide patterns of gene expression at 2 or 3 time points
throughout the progression of Ab pathology. However, they focused
only on either intermediate stages (Selwood et al., 2009), or early
and late stages (Reddy et al., 2004; Wu et al., 2006) of the plaque
pathology. In the current study we investigated the whole time
proﬁle from 2 to 18 months to monitor closely the transcriptional
changes that occur before and during the buildup of Ab pathology.
To follow the expression of individual transcripts during the
development of Ab plaque pathology, we constructed expression
proﬁles over time. This approach revealed 2 clusters of concerted
Fig. 2. Upregulation of gene transcripts during the development of beta amyloid protein (Ab) pathology inAPPswe/PS1dE9mice. (A) Geneswere clustered according to their expression
proﬁles over time in APPswe/PS1dE9 transgenicmice. Expression valueswere normalized against themean expression of all 2-month-old animals. Cluster 4 contains 3.9% and cluster 8
contains 67% signiﬁcantly regulated genes. The red solid line indicates the average expression proﬁle of all cluster members. The green solid line indicates the ﬁrst time point whenwe
detected Ab pathology in the mice. Note that gene upregulation coincided with the buildup of pathology and that no downregulated genes were detected. (B) Example proﬁles of
quantitative polymerase chain reaction (qPCR) validations for programmed cell death 1 (Pdcd1), triggering receptor expressed onmyeloid cells 2 (Trem2), toll-like receptor 2 (Tlr2), and
chemokine ligand 6 (Ccl6). Themicroarray data (solid lines) correlatedwith the qPCR data (dashed lines) for wild type (red) and transgenic (blue) animals over time. (C) The scatter plot
shows correlation data between qPCR and microarray for 17 genes in 15e18-month-old APPswe/PS1dE9 transgenic mice (R2 ¼ 0.85, p < 0.001).
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pronounced transcriptional changes detected from the age of 6
monthsonward, suggestinga linkbetweenthedevelopmentofplaque
pathologyandtranscriptionof thesegenes.However,becausewehave
not investigated time points in between 3 and 6 months, we cannot
further specify whether gene upregulation starts shortly before,
shortlyafter, or at the same timeas the appearanceof theﬁrst plaques.
4.1. Plaque development in APPswe/PS1dE9 mice is accompanied by
astroglial and microglial activation
We compared the signiﬁcantly regulated genes of our data
set with transcriptome databases for genes enriched in astrocytes,oligodendrocytes, neurons (Cahoy et al., 2008), and microglia
(Thomas et al., 2006) to investigate whether those genes, whose
expression is induced at the time that Ab pathology becomes
apparent in the cortex of the APPswe/PS1dE9, are expressed in
a particular cell type. The great majority of signiﬁcantly regulated
genes were expressed in microglia (53 genes: Afp, Aif1, Apbb1ip,
Apobec1, Arpc1b, Asb10, Atf3, B2m, Bcl3, Birc1b, Btk, Ccl3, Ccl4, Ccl6,
Cd14, Cd48, Cd52, Cd68, Cd84, Cd86, Cd9, Cst7, Ctsc, Ctsh, Ctsz, Ebi2,
Fcgr2b, Fcgr3, Gpnmb, Gpr65, Gusb, Igf1, Itgax, Klhl6, Lair1, Lilrb4,
Lpl, Lrmp, Ly86, Mamdc2, Mpeg1, Pon3, Rnase4, Rnaset2, Samsn1,
Slc11a1, Slc15a3, Spp1, Syngr1, Tlr2, Tnfsf13b, Trem2, Tyrobp).
Twenty of the signiﬁcantly regulated genes (Atf3, AU020206, B2m,
Bcl2a1b, C4b, Cd14, Cnn3, Ctsc Ctsz, Cybrd1, Frrs1, Gfap, Gusb,
Table 2
Table of the 30 most signiﬁcantly regulated Gene Ontology (GO) identiﬁers in clusters 4 and 8
ID Term Cluster number Annotated In cluster p
Biological process
GO:0002376 Immune system process 4 576 102 1.61Ee74
GO:0006955 Immune response 4 354 72 3.33Ee63
GO:0006952 Defense response 4 371 54 9.13Ee28
GO:0009605 Response to external stimulus 4 389 47 4.27Ee17
GO:0019882 Antigen processing and presentation 4 46 21 3.02E-16
GO:0045321 Leukocyte activation 4 191 29 2.93Ee15
GO:0001775 Cell activation 4 204 30 4.62Ee15
GO:0048002 antigen processing and Presentation of peptide antigen 4 29 16 4.72Ee14
GO:0006954 Inﬂammatory response 4 179 27 4.72Ee14
GO:0006952 Defense response 8 371 21 6.23Ee14
GO:0009611 Response to wounding 4 251 33 7.31Ee14
GO:0006955 Immune response 8 354 20 2.00E-13
GO:0046649 Lymphocyte activation 4 175 26 3.22E-13
GO:0030097 Hemopoiesis 4 194 27 2.29Ee12
GO:0002520 Immune system development 4 231 30 2.62Ee12
GO:0002376 Immune system process 8 576 22 1.20Ee11
GO:0048534 Hemopoietic or lymphoid organ development 4 217 28 2.79Ee11
GO:0006954 Inﬂammatory response 8 179 14 5.05Ee11
GO:0009611 Response to wounding 8 251 14 4.05Ee09
GO:0051239 Regulation of multicellular organismal process 4 251 28 1.46Ee08
GO:0002478 antigen processing and Presentation of exogenous
peptide antigen
8 17 6 2.25Ee08
GO:0002449 Lymphocyte-mediated immunity 8 78 9 2.25Ee08
GO:0006911 Phagocytosis, engulfment 8 9 5 2.97Ee08
GO:0002443 Leukocyte-mediated immunity 8 84 9 2.97Ee08
GO:0002474 Antigen processing and presentation of peptide antigen
via MHC class I
4 15 9 3.58Ee08
GO:0051707 Response to other organism 8 124 10 4.33Ee08
GO:0050764 Regulation of phagocytosis 8 10 5 4.34Ee08
GO:0050766 Positive regulation of phagocytosis 8 10 5 4.34Ee08
GO:0009605 Response to external stimulus 8 389 15 4.34Ee08
GO:0002252 Immune effector process 4 115 21 5.13Ee08
Cellular component
GO:0009986 Cell surface 4 163 27 3.21Ee16
GO:0042611 MHC protein complex 4 20 13 1.24Ee12
GO:0005886 Plasma membrane 4 1568 104 4.78Ee10
GO:0000323 Lytic vacuole 4 158 22 6.20Ee10
GO:0005764 Lysosome 4 158 22 6.20Ee10
GO:0009897 External side of plasma membrane 8 116 10 2.97Ee08
GO:0005773 Vacuole 4 177 22 4.27Ee08
GO:0009897 External side of plasma membrane 4 116 21 5.81Ee08
GO:0042612 MHC class I protein complex 4 12 8 9.12Ee08
GO:0009986 Cell surface 8 163 10 2.62Ee07
GO:0005764 Lysosome 8 158 9 1.72Ee06
GO:0000323 Lytic vacuole 8 158 9 1.72Ee06
GO:0005773 Vacuole 8 177 9 3.65Ee06
GO:0005886 Plasma membrane 8 1568 21 1.68Ee05
GO:0005576 Extracellular region 8 2041 24 6.18Ee05
GO:0016020 Membrane 4 6289 276 7.24Ee05
GO:0044421 Extracellular region part 4 1938 105 7.24Ee05
GO:0005615 Extracellular space 4 1828 100 8.17Ee05
GO:0042613 MHC class II protein complex 4 8 5 9.53Ee05
GO:0044459 Plasma membrane part 4 1216 72 1.24Ee04
GO:0044421 Extracellular region part 8 1938 22 3.24Ee04
GO:0005615 Extracellular space 8 1828 21 4.06Ee04
GO:0044459 Plasma membrane part 8 1216 16 4.40Ee04
GO:0016021 Integral to membrane 8 4812 39 2.12Ee03
GO:0031224 Intrinsic to membrane 8 4824 39 2.23Ee03
GO:0044425 Membrane part 4 5265 225 6.82Ee03
GO:0016021 Integral to membrane 4 4812 208 7.08Ee03
GO:0044425 Membrane part 8 5265 40 7.16Ee03
GO:0031224 Intrinsic to membrane 4 4824 208 7.98Ee03
Molecular function
GO:0019865 Immunoglobulin binding 8 9 5 2.97Ee08
GO:0032403 Protein complex binding 8 43 6 1.43Ee06
GO:0019955 Cytokine binding 4 62 14 1.53Ee06
GO:0008009 Chemokine activity 8 34 5 8.18Ee06
GO:0042379 Chemokine receptor binding 8 35 5 9.16Ee06
GO:0001664 G-protein-coupled receptor binding 8 48 5 3.89Ee05
GO:0004896 Cytokine receptor activity 4 52 10 3.49Ee04
GO:0005515 Protein binding 4 4413 200 6.72Ee04
GO:0001784 Phosphotyrosine binding 8 6 2 2.27Ee03
GO:0003796 Lysozyme activity 8 7 2 3.10Ee03
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Table 2 (continued )
ID Term Cluster number Annotated In cluster p
GO:0005125 Cytokine activity 4 196 17 3.68Ee03
GO:0005515 Protein binding 8 4413 36 3.75Ee03
GO:0045309 Protein phosphorylated amino acid binding 8 8 2 3.99Ee03
GO:0005509 Calcium ion binding 4 704 43 4.28Ee03
GO:0005102 Receptor binding 8 527 9 6.37Ee03
GO:0051219 Phosphoprotein binding 8 13 2 9.33Ee03
K.T.S. Wirz et al. / Neurobiology of Aging 34 (2013) 1328e13421338Lair1, Mamdc2, Osmr, Plxdc2, Ptx3, Rnaset2, Slc14a1) were at least
1.5-fold enriched in astrocytes, with 3 (Cybrd1, Gfap, Slc14a1) being
astrocyte-speciﬁc. It should be noted, however, that we found
C4B protein expression in microglia and not in astrocytes. Only 4
signiﬁcant genes were enriched in neurons (Ccl4, Igf1, Lpl, Syngr1).
None of the regulated genes was enriched in oligodendrocytes.
The upregulation of many microglia genes including Cd68,
amarker for activatedmicroglia, indicates an activation of microglia
by Ab. This is in line with other studies reporting that IBA1 positive
microglia express CD68 in AD mouse models (Bornemann et al.,
2001; Kamphuis et al., 2012). Activated microglia are an effective
response for the elimination of pathogens and are thought to
mediate the degradation and clearance of Ab (Boissonneault et al.,
2009; Chen et al., 2006). Furthermore, the upregulation of many
genes expressed in astrocytes indicates a clear involvement of
astrocytes in Ab pathology. Indeed, astrocytes are able to degrade
Ab (Wyss-Coray et al., 2003) and play an important role in the
induction of neuroinﬂammation in AD (Li et al., 2011). Overall, our
ﬁndings support earlier reports that astroglia become hypertrophic
and thatmicroglia tend to accumulate in and around senile plaques,
both in animal models and in AD patients (Johnston et al., 2011;Fig. 3. Protein expression of glial-ﬁbrillary acidic protein (GFAP), allograft inﬂammatory
Fluorescent immunostaining on wild type (WT) and APPswe/PS1dE9 (TG) animals at 15 mon
are shown in green; nuclei were stained with Hoechst and shown in blue. GFAP, IBA1, and C
and quantiﬁcation for GFAP, IBA1, and C4B protein during the development of plaque patho
GFAP, IBA1, and C4B validated the microarray and the immunostainings even though the uKamphuis et al., 2012; Olabarria et al., 2010) and that they exhibit
an activated phenotype (Yan et al., 2009) leading to the activation of
host defense mechanisms.
4.2. APPswe/PS1dE9 mice exhibit a well-controlled immune response
Glial activation leads to the production of pro- and anti-
inﬂammatory cytokines (Hanisch and Kettenmann, 2007; Li et al.,
2011). Indeed, the great majority of upregulated transcripts in the
APPswe/PS1dE9 mouse was involved in immune system related
processes, including many Cd antigens, chemokine ligands, and
members of the complement system. In contrast to earlier reports
(Hickman et al., 2008; Ruan et al., 2009), our data show that in
APPswe/PS1dE9 mice well-known proinﬂammatory mediators
(Il-1, Il-6, tumor necrosis factor a [Tnfa], interferon g, and Tgfß)
were not signiﬁcantly increased. Instead, we observed a strong
upregulation of immune suppressive mediators like polypeptide
growth factor 1 (Igf1) and triggering receptor expressed onmyeloid
cells 2 (Trem2). The production of proinﬂammatory cytokines such
as Tnfa might be suppressed by the upregulation of Fc receptor
gamma 2b (Fcgr2b) (Smith and Clatworthy, 2010), Igf1 (Gasparinifactor 1 (IBA1), and complement component 4b (C4B) in APPswe/PS1dE9 mice. (A)
ths. GFAP, IBA1, and C4B are shown in red; plaques were stained with thioﬂavine S and
4B protein were upregulated in TG animals. Scale bar: 50 mm. (B) Western blot analysis
logy. Protein levels are given as relative values to b-actin levels. Western blot data for
pregulation was less pronounced.
Fig. 4. Comparison of synaptic gene expression data from APPswe/PS1dE9 mice and
literature. Gene expression of well-known synaptic genes that were investigated in
another, but similar APP-PS1 transgenic mouse model (Dickey et al., 2003) or found to
be regulated in human AD patients (Bossers et al., 2010a) was studied in APPswe/
PS1dE9 mice using quantitative polymerase chain reaction (qPCR). Note that only
Nr4a1, Arc, and Egr1 are mildly downregulated (not signiﬁcant).
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programmed cell death 1 (Pdcd1) (Yao et al., 2009), molecules that
have been indicated to decrease the severity of (auto)immune
responses and to promote neuroprotective immune responses. As
Tnfa, together with interferon g, also stimulates Ab deposition by
inducing the production of Ab peptides and decreasing the secre-
tion of soluble APPs (Blasko et al., 1999), the successful reduction of
Tnfa is, therefore, a frequently investigated therapeutic strategy for
AD patients (Frankola et al., 2011; Park and Bowers, 2010). The
APPswe/PS1dE9 mouse with its naturally occurring inhibition of
Tnfa upregulation could possibly help to understand better which
genes contribute to low Tnfa levels.
Furthermore, our data suggest that the upregulation of Atf3 in
APPswe/PS1dE9 mice might serve as a control mechanism to limit
the amount of Ccl4 (Khuu et al., 2007) and to inhibit Tlr2-stimulated
inﬂammatory responses (Gilchrist et al., 2006; Liu et al., 2012;
Sabroe et al., 2005). An excessive immune response might also be
prevented by the upregulation of interferon regulatory factor 8
(Irf8) which negatively regulates MHC Class I molecules (Agrawal
and Kishore, 2000). In general, our data suggest that Ab invokes
a well-controlled immune response to buildup rather than a strong
inﬂammatory response in APPswe/PS1dE9 mice.4.3. The expression of genes involved in synaptic function and
plasticity is not altered in APPswe/PS1dE9 mice cortex
In our microarray and qPCR studies, we did not observe any
signiﬁcant transcriptional changes of genes with synaptic function in
the APPswe/PS1dE9 mice. We observed only a single signiﬁcantly
upregulated gene, Syngr1, with reported synaptic function. Syngr1 is
essential for short- and long-term potentiation in the hippocampus
(Janz et al., 1999) and it inhibits Ca2þ-dependent exocytosis (Sugita
et al., 1999). Syngr1 is localized to the membrane of small presyn-
aptic vesicles (Kedra et al., 1998) and facilitates the targeting of
synaptophysin to synaptic-like microvesicles in PC12 cells (Belfortand Kandror, 2003), a model system for synaptic vesicles. However,
a study in human postmortem tissue showed that Syngr1 is down-
and not upregulated in late onset AD patients (Liang et al., 2010).
Igf1 and Tlr2 are both strongly upregulated in the APPswe/
PS1dE9 mice. In addition to their role in the immune system they
have been implicated in neuronal functioning. Igf1 has neuro-
protective effects and promotes neurogenesis, development,
differentiation, synapse formation, and glucose utilization
throughout the brain (Torres-Aleman, 2000). Furthermore, IgfI
enhances cognitive performance, increases the levels of synaptic
proteins (Carro et al., 2006), and reverses Ab-induced neurotoxicity
(Jarvis et al., 2007). In humans, IGF1 plasma levels are reduced in
familial AD patients (Mustafa et al.,1999) and in aged subjects (Arvat
et al., 2000). Tlr2 is involved in adult neurogenesis (Rolls et al., 2007).
APP-PS1-Tlr2(-/-) mice show accelerated cognitive impairments
pairedwith increasedAb levels andTlr2 treatment in thesemice had
beneﬁcial effects by restoring the memory consolidation process
(Richard et al., 2008). In humans, a polymorphism in Tlr2 changes
the susceptibility to AD in a Chinese population (Yu et al., 2011). It is
possible that the upregulation of Igf1 and Tlr2 helps to prevent
neuronal damage in the frontal cortex of APPswe/PS1dE9 mice.
It has been suggested that amyloid might suppress mole-
cular mechanisms for memory, independent of neuron or synapse
loss (Dickey et al., 2003, 2004). However, Egr1, Arc, and Nr4a1, 3
immediate-early genes associated with long-term potentiation and
memory consolidation, were the only genes associated with memory
that showed a nonsigniﬁcant, decrease in the cortex of aged APPswe/
PS1dE9 mice. This decrease was comparable with the decrease in the
cortex and hippocampus of another APPþPS1 mouse model reported
by Dickey and colleagues.
It is noteworthy that some studies show cognitive deﬁcits in
APPswe/PS1dE9 mice as early as 2e3 months (Pillay et al., 2008), 4
months (Bonardi et al., 2011), and 5 months (Timmer et al., 2010) of
age. A larger body of evidence shows cognitive deﬁcits at 6 months
(Filali and Lalonde, 2009; Jankowskyet al., 2005; Kilgore et al., 2010;
Lagadec et al., 2012;Minkeviciene et al., 2008) with the exception of
a single study that could not detect cognitive deﬁcits at that time
point (Savonenko et al., 2005). Other studies have only investigated
later time points and have consistently found cognitive deﬁcits in
older APPswe/PS1dE9 mice (Gimbel et al., 2010; Hooijmans et al.,
2009; Melnikova et al., 2006; O’Leary and Brown, 2009; Toledo
and Inestrosa, 2010). Most relevant to the cortical gene expression
data presented here, Filali and Lalonde (2009) demonstrated that
6-month-old APPswe/PS1dE9 mice show deﬁcits in nest building,
which is indicative for prefrontal cortex dependent step-by-step
planning and organization. Our transcriptional proﬁling data
suggest that frontal cortex-dependent cognitive deﬁcits in APPswe/
PS1dE9 mice are not because of transcriptional changes of genes
involved in learning and memory in cortical neurons. Because
behavioral alterations can be caused byneuroinﬂammation (Arnaud
et al., 2006; Fan et al., 2007; Labrousse et al., 2012; Zhang et al.,
2012), the robust cognitive deﬁcits in the APPswe/PS1dE9 mice
starting at 6 months might partly be the result of changes in the
expression of genes that govern an immune reaction. It should
be noted that gene expression changes in other brain areas, such as
the hippocampus, are very likely to contribute to frontal cortex-
independent behavioral deﬁcits.
4.4. APPswe/PS1dE9 mice transcriptional proﬁles do not resemble
human AD data
In the present study we compared transcriptional changes in the
frontal cortex of APPswe/PS1dE9 mice and AD patients during the
development of AD pathology. In the human sporadic AD brain we
observed that the appearance of AD neuropathology in Braak stage
K.T.S. Wirz et al. / Neurobiology of Aging 34 (2013) 1328e134213403 is preceded by transcriptional changes in genes related to
neuronal plasticity and activity in Braak stage 2 (Bossers et al.,
2010a). We have not observed any evidence for changes in genes
involved in these processes in the APPswe/PS1dE9 mouse. When
comparing gene expression changes in end-stage AD patients
(Braak stages 5 and 6) and aged APPswe/PS1dE9 mice, only 3 genes
(Plxdc2, Slc14a1, and C4b) showed a signiﬁcant regulation in both
the transgenic APPswe/PS1dE9 mice and the sporadic human AD
data sets. Blood-group antigen Slc14a1, an erythrocyte urea trans-
porter, has so far no clear function in the nervous system (Bagnasco,
2006). Plxdc2 has been shown to coordinate cell proliferation and
differentiation in the developing nervous system (Miller-Delaney
et al., 2011) and in cancer (Carson-Walter et al., 2001; Davies
et al., 2004; Rmali et al., 2007). Our ﬁnding that both genes are
upregulated in an ADmouse model and in patients with Ab plaques
might suggest a yet unknown function for these genes in Ab
pathology. C4b, which is part of the classic activation pathway of
the complement system, has been described to be highly expressed
in and around plaques of the Arctic, Tg2576 (Fonseca et al., 2011)
and APPþPS1 (Dickey et al., 2003) mouse models for AD and to
prevent early stages of autoimmune disease (Paul et al., 2002).
These results, together with our ﬁndings, suggest that C4b plays
a role in Ab-induced immune response.
In addition, we investigated whether genes that are consistently
altered in multiple human AD microarray datasets (BCL2, BTG1,
CD59, GTF2I, MXI1, SLC6A12, CYCS, and CHCHD2) (Blalock et al.,
2004; Bossers et al., 2010a; Emilsson et al., 2006; Parachikova
et al., 2007; Xu et al., 2006) are also altered in the APPswe/
PS1dE9 mouse. We found that none of these genes are signiﬁcantly
altered in the cortex of APPswe/PS1dE9 mice. It should be noted
that APPswe/PS1dE9 mice carry mutations in the APP and the
PSEN1 gene, though these genes are not mutated in sporadic AD
patients. The molecular mechanisms leading to plaque formation
and memory deﬁcits in these mice and sporadic AD patients might
therefore be substantially different.
Functional annotations of regulated gene clusters in the trans-
genic mouse model hardly overlap with human data (Bossers et al.,
2010a). Though the mouse only shows alterations in immune-
related genes, the development and progression of AD in the
human prefrontal cortex is associated with many (early) changes
regarding synaptic activity, plasticity, transcription, metal ion
binding, differentiation, and proliferation. The APPswe/PS1dE9
mouse is therefore not suitable for studying these aspects of AD,
especially early synaptic changes.
4.5. The APPswe/PS1dE9 mouse can be a model for AD-related
immune response
Because we predominantly detected alterations in immune-
related transcripts in APPswe/PS1dE9 mice, we speciﬁcally inves-
tigated whether we could ﬁnd commonalities between human AD
and the APPswe/PS1dE9 mouse in the regulation of immune-
related transcripts other than the previously discussed genes
TREM2 and C4B. Indeed, C3, CXCL10, CXCR4, HLA-DRB1, ICOSLG,
IRAK3, KLHL6, RGS1, SERPINA3, and TGFB1 showed a trend toward
upregulation in the cortex of the APPswe/PS1dE9 and the human
AD data sets. Interestingly, most of these genes have been impli-
cated in AD or amyloid pathology. Upregulation of the complement
component C3 has been proposed to reduce Ab plaque burden and
neuronal loss by modulating microglia toward a classic M1-like
activated phenotype (Maier et al., 2008) and activates Cd68. C3
upregulation itself is a result of anti-inﬂammatory Tgfb1 upregu-
lation (Wyss-Coray et al., 2002). Tgfb1 also upregulates Irak3,
a negative regulator of Toll-like receptor signaling (Standiford et al.,
2011). The chemokine ligand CXCL10 is increased in brains of ADmouse models (Duan et al., 2008; Israelsson et al., 2010) and in
cerebrospinal ﬂuid of patients with mild AD (Galimberti et al.,
2006), and chemokine receptor CXCR4 is downregulated in the
Tg2576 mouse model for AD, but upregulated in AD patients
(Parachikova and Cotman, 2007). The major HLA-DRB1 is expressed
in antigen presenting dendritic cells and HLA-DR alleles might
account for differences in Ab-reactive T cells and Ab immunoge-
nicity (Zota et al., 2009). Polymorphisms in SERPINA3 have been
implicated to modify the risk for AD associated with the apolipo-
protein E ε4 allele (DeKosky et al., 1996; Kamboh et al., 1995, 2006).
Inﬂammation is a key contributing factor in the pathology of AD
and many hallmarks of neuroinﬂammation (such as activation of
microglia and the complement system, increased cytokine expres-
sion) are observed in tissue of AD patients (Eikelenboom et al.,
2010, 2011; Frank-Cannon et al., 2009). Studying the immune
response in AD is therefore essential for understanding the disease
and developing therapies. Our study in the APPswe/PS1dE9 mouse
model has uncovered the full temporal proﬁle of transcriptional
changes in immune genes that are associated with Ab pathology,
and provides a valuable resource to further elucidate the Ab-
induced immune response in AD.
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